APTOF — Aptose Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting
Brief: Aptose Biosciences Announces Arrangement Agreement For Acquisition By Hanmi Pharmaceutical
Aptose Biosciences Q3 net loss narrows
Brief: Aptose's Tuspetinib Exceeds Expectations When Combined With Standard Of Care Treatment Across Diverse Populations Of Newly Diagnosed AML
Brief: Aptose Reports Tuspetinib Improves Standard Of Care Treatment Across Diverse Populations Of Diagnosed AML In Trial
Brief: Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval To Dose Escalate In Phase 1/2 Tuscany Trial Of Frontline Triple Drug Therapy With Tuspetinib Amid Complete Responses And Favorable Safety In First Cohort
Brief: Aptose Announces Reverse Share Split
Brief: Aptose Biosciences Inc Files Prospectus Related To Resale Of Up To 12 Million Common Shares By Selling Stockholders- SEC Filing
Brief: Aptose Enters Into $25 Million Committed Equity Facility And Establishes New At-The-Market Facility
Aptose Biosciences rises on safety results from early-stage cancer therapy trial
Brief: Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
Brief: Aptose Biosciences Announces Closing Of $8 Million Public Offering
Brief: Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
Brief: Aptose Biosciences Files Prospectus Relates To Offering Of Up To 21.5 Mln Common Shares Together With Warrants -SEC Filing
Brief: Aptose Biosciences On Oct 1, Got Staff Nasdaq Staff Determination Letter That Co Did Not Meet Terms Of Extension To Regain Compliance
Brief: Aptose Biosciences Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq